We serve Chemical Name:3,5-DIMETHYL-1-(3-METHYL-BENZYL)-1H-PYRAZOL-4-YLAMINE CAS:1185550-19-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3,5-DIMETHYL-1-(3-METHYL-BENZYL)-1H-PYRAZOL-4-YLAMINE
CAS.NO:1185550-19-9
Synonyms:3,5-DIMETHYL-1-(3-METHYL-BENZYL)-1H-PYRAZOL-4-YLAMINE
Molecular Formula:C13H17N3
Molecular Weight:215.29
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:
Exact Mass:
LogP:
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 3,5-DIMETHYL-1-(3-METHYL-BENZYL)-1H-PYRAZOL-4-YLAMINE chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3,5-DIMETHYL-1-(3-METHYL-BENZYL)-1H-PYRAZOL-4-YLAMINE physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3,5-DIMETHYL-1-(3-METHYL-BENZYL)-1H-PYRAZOL-4-YLAMINE Use and application,3,5-DIMETHYL-1-(3-METHYL-BENZYL)-1H-PYRAZOL-4-YLAMINE technical grade,usp/ep/jp grade.
Related News: There are also new directives that relate to US citizens. 3,5-DIMETHYL-1-(3-METHYL-BENZYL)-1H-PYRAZOL-4-YLAMINE manufacturer Though Innova previously applied for a regulatory green light, the test has not been authorized or approved by the FDA for use in the U.S.—however, during inspections of the company’s California facilities in March and April, FDA investigators said they found the test was already being sold and distributed. 3,5-DIMETHYL-1-(3-METHYL-BENZYL)-1H-PYRAZOL-4-YLAMINE supplier Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country. 3,5-DIMETHYL-1-(3-METHYL-BENZYL)-1H-PYRAZOL-4-YLAMINE vendor There are also new directives that relate to US citizens. 3,5-DIMETHYL-1-(3-METHYL-BENZYL)-1H-PYRAZOL-4-YLAMINE factory Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country.